CN104470898B - 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 - Google Patents

环烷基甲酸类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN104470898B
CN104470898B CN201480001853.5A CN201480001853A CN104470898B CN 104470898 B CN104470898 B CN 104470898B CN 201480001853 A CN201480001853 A CN 201480001853A CN 104470898 B CN104470898 B CN 104470898B
Authority
CN
China
Prior art keywords
general formula
thio
pharmaceutically acceptable
tautomer
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480001853.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104470898A (zh
Inventor
彭建彪
孙飘扬
兰炯
顾春燕
李晓涛
刘柏年
韩春周
胡齐悦
金芳芳
董庆
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Shengdi Pharmaceutical Co ltd
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201480001853.5A priority Critical patent/CN104470898B/zh
Publication of CN104470898A publication Critical patent/CN104470898A/zh
Application granted granted Critical
Publication of CN104470898B publication Critical patent/CN104470898B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201480001853.5A 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 Active CN104470898B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480001853.5A CN104470898B (zh) 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013101749906 2013-05-13
CN201310174990 2013-05-13
PCT/CN2014/076447 WO2014183555A1 (zh) 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用
CN201480001853.5A CN104470898B (zh) 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN104470898A CN104470898A (zh) 2015-03-25
CN104470898B true CN104470898B (zh) 2016-04-06

Family

ID=51897690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480001853.5A Active CN104470898B (zh) 2013-05-13 2014-04-29 环烷基甲酸类衍生物、其制备方法及其在医药上的应用

Country Status (20)

Country Link
US (1) US9637484B2 (enExample)
EP (1) EP2998296B1 (enExample)
JP (1) JP6440690B2 (enExample)
KR (1) KR102240158B1 (enExample)
CN (1) CN104470898B (enExample)
AU (1) AU2014267974B2 (enExample)
BR (1) BR112015027303B1 (enExample)
CA (1) CA2923269C (enExample)
CY (1) CY1120515T1 (enExample)
DK (1) DK2998296T3 (enExample)
ES (1) ES2668721T3 (enExample)
HU (1) HUE037512T2 (enExample)
LT (1) LT2998296T (enExample)
MX (1) MX362747B (enExample)
NO (1) NO2998296T3 (enExample)
PL (1) PL2998296T3 (enExample)
PT (1) PT2998296T (enExample)
TR (1) TR201807104T4 (enExample)
TW (1) TWI654172B (enExample)
WO (1) WO2014183555A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110467571A (zh) * 2018-05-11 2019-11-19 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
WO2020088641A1 (zh) * 2018-11-02 2020-05-07 江苏恒瑞医药股份有限公司 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
RU2783862C1 (ru) * 2018-11-02 2022-11-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Совместное применение соединения a и соединения b для получения лекарственных средств для лечения подагры или гиперурикемии

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3305768T (pt) * 2015-05-27 2020-08-03 Jiangsu Hengrui Medicine Co Sal de sódio de um inibidor do transportador do ácido úrico e forma cristalina do mesmo
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
EP3388420B1 (en) * 2015-12-07 2022-06-22 Hinova Pharmaceuticals Inc. Quinoline compounds, preparation method thereof, and use thereof as urate transporter inhibitor drug
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108201529B (zh) * 2016-12-16 2021-10-08 江苏恒瑞医药股份有限公司 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法
NZ765226A (en) * 2017-11-23 2022-11-25 Medshine Discovery Inc Crystal form of urat1 inhibitor, and preparation method therefor
CN110452168B (zh) * 2018-05-07 2022-03-15 中国医学科学院药物研究所 N-苯基-n-喹啉羧酸类化合物及其制法和药物用途
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
AU2023285760B2 (en) * 2021-05-19 2025-07-10 Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. Quinoline Mercaptoacetate Sulfonamide Derivative, Intermediate, Pharmaceutical Derivative Or Formulation, And Preparation Method And Use Therefor
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820515A1 (en) * 2004-11-29 2007-08-22 Japan Tobacco, Inc. Nitrogen-containing fused ring compound and use thereof
CN103068801A (zh) * 2010-06-16 2013-04-24 亚德生化公司 硫代乙酸盐化合物、组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
TW200916098A (en) 2007-06-14 2009-04-16 Teijin Pharma Ltd Agent for lowering uric acid level
CN103058944B (zh) 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物
JPWO2010044403A1 (ja) 2008-10-15 2012-03-15 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
EP2488020B1 (en) 2009-10-13 2016-12-14 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
JP5709146B2 (ja) * 2010-06-16 2015-04-30 アルデア バイオサイエンシーズ インク． フェニルチオ酢酸化合物、組成物、および、その使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820515A1 (en) * 2004-11-29 2007-08-22 Japan Tobacco, Inc. Nitrogen-containing fused ring compound and use thereof
CN103068801A (zh) * 2010-06-16 2013-04-24 亚德生化公司 硫代乙酸盐化合物、组合物及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS号：1065092-18-3;REGISTRY;《STN ON THE WEB》;20081023;第3页 *
CAS号：882138-16-1;REGISTRY;《STN ON THE WEB》;20081023;第2-3页 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110467571A (zh) * 2018-05-11 2019-11-19 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
CN110467571B (zh) * 2018-05-11 2021-02-26 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
WO2020088641A1 (zh) * 2018-11-02 2020-05-07 江苏恒瑞医药股份有限公司 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
CN112512526A (zh) * 2018-11-02 2021-03-16 江苏恒瑞医药股份有限公司 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
RU2783862C1 (ru) * 2018-11-02 2022-11-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Совместное применение соединения a и соединения b для получения лекарственных средств для лечения подагры или гиперурикемии

Also Published As

Publication number Publication date
NO2998296T3 (enExample) 2018-08-11
JP2016520072A (ja) 2016-07-11
CY1120515T1 (el) 2019-07-10
CN104470898A (zh) 2015-03-25
KR20160006207A (ko) 2016-01-18
WO2014183555A1 (zh) 2014-11-20
MX2015015393A (es) 2016-03-15
EP2998296A4 (en) 2016-12-14
HK1205118A1 (zh) 2015-12-11
TWI654172B (zh) 2019-03-21
BR112015027303B1 (pt) 2023-04-25
HUE037512T2 (hu) 2018-08-28
EP2998296A1 (en) 2016-03-23
DK2998296T3 (en) 2018-05-22
US20160108035A1 (en) 2016-04-21
AU2014267974A1 (en) 2015-11-12
CA2923269A1 (en) 2014-11-20
LT2998296T (lt) 2018-08-10
TW201443010A (zh) 2014-11-16
MX362747B (es) 2019-02-05
ES2668721T3 (es) 2018-05-21
JP6440690B2 (ja) 2018-12-19
KR102240158B1 (ko) 2021-04-15
PL2998296T3 (pl) 2018-12-31
AU2014267974B2 (en) 2018-08-30
CA2923269C (en) 2023-02-14
US9637484B2 (en) 2017-05-02
BR112015027303A2 (enExample) 2017-09-05
EP2998296B1 (en) 2018-03-14
TR201807104T4 (tr) 2018-06-21
PT2998296T (pt) 2018-06-15

Similar Documents

Publication Publication Date Title
CN104470898B (zh) 环烷基甲酸类衍生物、其制备方法及其在医药上的应用
CN114195799B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
JP6752235B2 (ja) 核内輸送調節因子およびその使用
CN106220644B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN110121343B (zh) 用作gpr120调节剂的双环化合物
CN111712496A (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
WO2005035501A1 (ja) 新規オレフィン誘導体
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
CA3053068A1 (en) 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
CN105524053A (zh) 四氢苯并噻吩化合物
WO2018137655A1 (zh) 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
CN101481323A (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
JPH07502007A (ja) 治療用のベンズアザピン化合物
WO2016026372A1 (zh) 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
TW202029963A (zh) 1,2,3,4-四氫喹㗁啉衍生物及其製備方法和應用
RU2818456C1 (ru) Соединение, используемое в качестве ингибитора бромодоменсодержащих белков, и композиция
HK1205118B (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
JP6837578B2 (ja) 発明の名称アミノアルコール誘導体、その医薬組成物および使用
WO2025031361A1 (zh) 磺酰胺类化合物作为制备治疗癌症药物的用途
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途
EP0905134B1 (en) Piperidine derivatives as LTD4 and H1 antagonists
CN114716504A (zh) 一种生长激素促分泌素衍生物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205118

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1205118

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230919

Address after: 361026 room 53, floor 1, building A19, Xiamen biomedical industrial park, 2036 wengjiao West Road, Haicang District, Xiamen City, Fujian Province

Patentee after: Fujian Shengdi Pharmaceutical Co.,Ltd.

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 200245 No. 279, Wen Jing Road, Shanghai, Minhang District

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.